Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

XVIVO, Audiocast with teleconference, Q2'24

By Inderes7/12/2024, 12:00 PM
Xvivo Perfusion

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christoffer Rosenblad
00:00 - 15:15

Thank, you so much and welcome to XVIVO. This earnings call is for the second quarter of 2024. As we can see on the first slide, we have today's presenters here. It's me, Christoffer Rosenblad, CEO of XVIVO, and Kristoffer Nordström, CFO, joining in from Philadelphia today. If we proceed to the second slide in the deck. We see Q2 financials at a glance, and I'm proud and happy to report the strongest quarter in XVIVO's history, with Q2 showing improvements in top line as well as EBITDA. More importantly, Q2 indicates that XVIVO is a scalable business model with improving margins and increasing sales. We continue and will continue to invest in the organization for future growth. Sales reached a record 210 million Swedish kronor. Our gross margins continue to show strength. We have planned and reported that we plan to improve the abdominal gross margin to 70% by 2027 or earlier. As we reach economies of scale in production, we see that we continue to produce according to that goal. EBITDA shows a strong improvement to 24%. Kristoffer Nordström, our CFO, will delve into the details on sales, gross margins, and EBITDA later in this presentation. I also want to mention that the growth for thorax is picking up, mainly due to higher expense activity during the quarter. Historically, we have seen solid growth from Europe in the XPS, and now we see that growth is increasingly coming from the US. There is high interest from new customers starting with trial programs, and we see that former low-volume customers are increasing their activity level. With that, let's move on to year-to-date (YTD) financials at a glance. As you can see on slide three, we observe a similar picture. For the first six months, as observed in the quarter, the key takeaways for the first half are growth. Growth is still primarily coming from increased activity in existing customers and a strong market. We continue to see high interest from new customers, especially noted after an event in April. And we note that this interest has started to convert to active customers. We can also conclude that sales from products are picking up faster than sales from services, even though we have a fantastic service offering with very good quality and excellent customer feedback. Despite heavy investments primarily in commercial and field force, we can conclude that the revenue model is scalable. In other words, we see that it gets converted to gross margin and EBITDA. Lastly, and most importantly, it's worth mentioning that projects are progressing according to plan. The heart project is on time, and by that, the production capacity project where we invest to scale up volumes to ten times today's volumes for disposables is running in line with communicated timelines. I'm happy to report that the first milestone for the Kinesis Transport is met, and we now will have production volume for our launch in Q3. Probably after the vacation period in the U.S. As we reported earlier, the project for full-scale production of disposables for the heart, liver, and kidneys is estimated to be completed by the end of Q2 next year. So, we still have a year to go. And with these first two slides, we will move on to the Q2 highlights on slide four. And then we can go directly to slide five where we go over what happened. I know I mentioned this last quarter, but some news needs repetition. So, we start with the report from this year's ISHLT conference in Prague in April. It is by far the largest and most important conference for heart and lung transplantation. And I want to emphasize again that it was the most selected exhibitor. And the result from the EU study with XVIVO technology was the most selected scientific session in the whole program. We also held two extremely well-attended industry symposia during the conference, where we received extremely positive feedback from customers about the scientific content, and they said it was even better than most of the regional programs. As I said earlier, we can already see, by late Q2, the impact of the conference in an increased interest for our lung and heart technologies. I also want to mention again the fantastic results from your heart study shown on slide six. It's, uh, I've never seen such good results before in my life. And there are three key takeaways from this study. One notable point is that, to our knowledge, this is the first randomized controlled trial with a superiority design in heart-lung transplantation, which shows the confidence clinicians have in our technology. Two, the HOPE group, where HOPE stands for Hypothermic Oxygenated Perfusion. In other words, pumps equipped with XVIVO technology showed an improvement of 61% for severe PD versus the control group. This is a highly important improvement, given that PGD is the leading cause of early mortality after heart transplantation. And we know that PD negatively affects long-term survival. A key takeaway is that all parts were deemed transplantable after perfusion. This is important to highlight since cold perfusion offers a safety advantage during transportation. On top of that, an ISP 2019 trial presented during ISD. I also want to mention the Pegasus trial, or Pegasus English study, led by Professor Liberty. It is progressing according to plan. We believe that even though this trial is relatively small with seventy-seven patients, it has the potential to revolutionize how logistics for heart transplants are performed. This is the first proof that our technology can provide both patient benefits and cost benefits for healthcare systems around the world. And with that, we turn to slide seven, where we will also continue to focus on the heart. And some great news around DCD donors and heart trials. Approval has been granted to study DCD donors. Direct procurement implies that transplants are performed without prior normothermic regional perfusion (NRP), and the proportion of the donor pool coming from DCD donors is comparably large in some countries and is growing very rapidly. So for example, in the US it's already 36%, and in Benelux it's approximately 58%. And if we want to substantially increase the number of transplants, we need to prove that DCD hearts can be transplanted in a safe, cost-efficient and practically feasible way with good patient outcomes. And this study is designed to show that. The earlier experience we have from liver and kidney transplants shows very good clinical outcomes, indicating that it is possible. So the concept in itself is proven. We have also seen in pre-climinal settings on hearts that using the XVIVO heart technology on DCD direct procurement shows good results. And lastly, as we have reported earlier, our DCD study in the US for regulatory approval includes DCD hearts. The company hopes and believes that we will have strong evidence when these two studies are concluded. And with that, we will turn to another organ, more precisely, the lungs. We have seen in both Q1 and Q2 good results and increased usage of EVLP for lungs. And we can see that the pressure from mainly the American political system to increase the number of transplants has had a very positive impact. We can also see that the hub models we have talked about before, or centralized perfusion models, help to drive growth. We now have the 'bridge' in Scandinavia actively recruiting. And we know Paris has a hub which now has three clinics participating; all these hubs enable us to make more transplants with fewer resources. I also want to mention in the US that we have deep collaboration with, for example, lung engineering. That collaboration has also proven to be very fruitful. The other trend we see with a positive effect and more support on the ground is an increasing interest for EVLP and setting up pre-programmed systems. And as I mentioned earlier, we have seen that some of that interest has turned into more usage of EVLP, and some of the interest has resulted in new EVLP programs being set up both in Europe and the US. And this is really exciting news. And we know that with more EVLP programs, we get more patients the chance of a lung transplant and hence not dying waiting for a new lung. And with that, we go straight into the abdominal portfolio. And during the last year, we've seen more than 20 publications on the liver assist technology showing improved patient outcomes on both DBD and DCD grafts after transplantation. This quarter, long-term survival data was published on extended criteria DBD livers and showed very good results. We are very pleased to both read this and very proud of what our technology can accomplish. And we can see in this study that the five-year outcome for organ survival is 87% in the liver group, which in itself is a very strong result. And I think it gets even more clear if we show it compared to the control group, where the result was 52%, which was standard of care, which is the 'beer cooler' type of transport with, uh, with ice and a solution. I have mentioned before also that last quarter, we had a Lancet publication showing that livers can be safely perfused for up to 20 hours and we can eliminate the need for nighttime liver transplants if we use this technology. And I think this again is a great example where we can demonstrate improved graft survival and also improve work-life balance for our customers. Lastly, as stated earlier, the production scale-up to ten times today's volumes is progressing according to plan. We have reached our first milestone and hence we are now ready to launch kidney transplants also in the United States. And with that, we leave the highlight section and turn to our clinical pipeline, which is described on slide ten. And we can go straight actually to slide 11 where we see the regulatory status, the clinical trials, and our tentative timelines. And I'm happy to report that nothing has changed since the last time we met. So I will repeat what I said in April. In the US, the heart trial is progressing according to plan, and our clinical team is working very hard to include all clinics into the trial. The interest is very high to be part of the trial, and we are literally doing our utmost to make sure that we can meet that interest. As also mentioned before, in Europe, we have handed in our technical documentation for review according to our timeline. We are aiming for a CE mark in Europe in Q4 2024. It's important to mention that we can't affect the review time to 100%. The good news is that the notified body has been very responsive, and even though they have a high workload under MDR, they have been really working together with us. Also, the Swedish MPA is responsive and delivering on time. The uncertainty we face is how fast EMA, or the European Medicines Agency, can handle the review? We have done what we can. In other words, handing in product and clinical files with good quality and on time. In Australia and New Zealand, we have already seen high usage of the product of the heart product. In this case, the regulatory approval will be pending the CE mark in Europe, but we are encouraged to see the continued high usage of approximately 30% of all hearts in Australia going on the XPS technology, on a compassionate use basis. We have also previously reported that the liver assist device has been granted breakthrough device designation by the FDA. This would mean that we get a faster route through the FDA PMA process. It is also a quality stamp that the products are innovative and fulfill a need in the market. We have started to invest in an organization to run the study, and we are preparing the FDA documentation. The aim is to hand in the IDE application at the end of this year. And with that, we have concluded the first part of the presentation and I will hand over to my CFO, Kristoffer Nordström, who will present the financial performance of the quarter.

Unknown 1
15:20 - 15:20

Thankaryou.

Kristoffer Nordström
15:20 - 15:21

So.

Unknown 1
15:21 - 15:21

Deck.

Kristoffer Nordström
15:22 - 25:02

Yes, as Mr. Rosenblad started off this call, it was a financially strong quarter. We're very satisfied. Happy about that? Basically, we're doing many things right at the moment, and that starts to pay off. And we should, you know, just continue to deliver in that way. Of course, sales came in at record levels in Q2. So did EBITDA. Um, but last but not least, our operating cash flow was also strong, which is delightful, of course. Uh, but moving to the numbers, net sales in Q2 reached 210 million SEK. This is a new record. As Kristoffer mentioned, we achieved 35% organic growth in local currencies. The overall gross margin remained stable. No surprises, really. Uh, 75%, the same as last year. EBIT increased in Q2, reaching 16% versus 10% last year. This increase was mainly driven by our increased sales, although we continue to invest in the organization. Uh, but as you know, we have done that in a fairly controlled manner so far. EBITDA in Q2 was 24%, compared to 19% last year. Overall, it was a good quarter where we continued to sequentially improve both top-line and profitability. Additionally, looking at the year-to-date numbers, it looks promising. We reached 396 million SEK in sales. That's a growth of 34% in local currencies, with EBIT at 13% and EBIT up 22%. Both of these measures are significantly better than last year. Um, let's touch a little on the outlook as we look ahead into the next quarter. It is worth mentioning that the third quarter is normally a sequentially weaker quarter than the second quarter. That has been our experience. Most often, this is due to factors somewhat out of our control, such as reduced activities during summer at the sites, but we will do what we can to maintain momentum. Uh, that has been our learning from the past. When it comes to EBITDA, this quarter was outstanding, as mentioned, at 24%. This measure can, of course, vary a bit from quarter to quarter. Um, and we continue to invest in and grow our organization, as you know. But what we demonstrated this quarter is that our current business model is scalable and already profitable at these lower levels of sales that we've seen this year and last year.< right tag> <year> Moving back to thoracic and revisiting Q2. Uh, it was a very strong quarter with sales coming in at 141 million SEK, and organic growth for disposables was 40%. The main driver, consistent with previous quarters, is LP, which is encouraging. Specifically, in North America, we observed LP growth of 40% in Q2 and more than 60% year to date. So, overall, it was a very robust development and very encouraging. We are starting to see the results now. Results now from the reorganization that we conducted last year indicate that sales, not to be forgotten, grew 12% versus Q2 of last year and have also grown 12% year to date. And that's driven by the increase in the number of transplants, but also by our price increases. On the safe side, it's also great to share that we had strong sales in Q2 of 19 million SEK, and that comes from a variety of compassionate use supported by the strong evidence presented at ISHLT, but also revenue from our US heart trial. So, we are starting to see some good numbers now, including in sales, despite the fact that the products have not yet been approved anywhere. Gross margin for disposuploadables in Q2 was 85%, which is in line with previous quarters. Moving over to abdominal. Net sales amounted to $47 million, which represents another record quarter as well. Organic growth in disposables at 36%. Um, if you also include machines, which makes a bit more sense on the abdominal side, here it's more frequent that we actually sell liver assist devices. If you include machines, the sales growth was actually 53%, which is very strong. Liver sales accounted for 72% of total abdominal sales, and kidney sales amounted to approximately 10 million SEEP, bringing us close to 20 million year to date. As Kristoffer mentioned, we have increased our production capacity and improved that capacity in Q1 and Q2, and we now have enough supply to start re-engaging with customers who have expressed interest in our technology, which is exactly what we've been waiting for. Gross margin for disposables came in at 63%, versus 70% last year. It's temporarily weighed down by costs associated with our interim solutions for production capacity. And then I think you can expect to see that also in Q3, Q4. We need to invest additional funds to ensure that we can continue to provide capacity, simply put. Finally, moving over to the business area of services. Sales in Q2 came in at 23 million SEK. Uh, and that came from 126 recovery cases. Uh, and that represents a modest sales growth. Transport activity at our customers increased by 10% in Q2, but we still suffer from lower cases versus last year due to the loss of two high volume centers in 2023. So, we have added new customers in Q4. We have simply not yet recovered and grown our case volumes. And that's also reflected in the numbers, of course. As we continue to develop our market strategy for organ recovery, we'll focus on that in Q3 and Q4. We are also working and looking into expanding our offering, not only providing organ recovery services, but also exploring NRP. We have had a very successful pilot case with a prominent U.S. hospital. And there is interest from other hospitals to have us help them execute on such a program as well. Uh, we are also looking into HOPE perfusion services. Hope to see a pilot in the second half of the year there as well. Most of the hospitals run their programs perfectly well because we are training them. We are there for them, so to say. If there are cases where new centers want to come on board and they also want us to offer perfusion services, we should absolutely be able to offer that as well. So, that's what we're looking into: another initiative. Uh, as a final comment on services, I would like to add that we want to and will start to engage our clinical services team with our top trial centers. So, who wants to learn how? Are there any centers today? Wants to learn how we can help them grow their thoracic transplant programs, not only after the trial but also during the trial. So those are dialogues that we are also having at the moment. So, we are carefully optimistic that we should end. And this year also ended on a high note for services. No doubt about that. Moving on to EBITDA, as we have covered extensively, it was indeed a solid quarter with a 24% increase. Well, we're at 20%, and the trend is developing nicely. We have stated it many times before, but our ambition is to continue to improve EBITDA year on year. Absolutely, we will do this step by step. What we aim to achieve is maintaining a healthy balance between sales growth and our ambition to assess growth and profitability. And we demonstrated this quarter that we're definitely on the right track. Final slide on my side, as always. Financial position and cash flow were mentioned at the beginning. Uh, good quarter here as well. Q1 was cash positive from operating activities, amounting to $25,000,006. Investment amounted to 48 million SEK, primarily spent on the US clinical trials and investments in the machine fleet, leading to a total cash flow of -27,000,006. We ended the quarter with a solid cash position of $481 million. And, uh, that was everything from me. For now, I'm happy to receive questions. So, I'm handing the word over to you again, Christoffer.

Christoffer Rosenblad
25:08 - 28:33

Thank you so much. We will just have two quick slides on the outlook. And I will start, as always, on the long-term picture. We're here for the long game. And it's important to establish a long, long-term perspective. The demand for transplants is still ten times higher than supply today, according to the WHO. I also want to mention that the sales value of machine perfusion is approximately ten times higher than that of static cold storage. So, there is a large market opportunity and a chance to improve life for patients with end-stage organ failure through machine perfusion. Our service models have proven to increase the number of organs that can be used for transplantation, especially in the fast-growing DCD organ pool. The main growth drivers are superior clinical results from machine perfusion, and the fact that service models reduce complexity and time for the transplant clinic. Hence, machine perfusion and service models are normal, and DCD grafts will drive growth in the near to medium term future. But lastly, to grow all the way to ten times the number of transplants, the company believes is possible with the current human donors. However, over time, new innovative sources of organs will probably be used. One example is xenografts or grafts from animals other than humans. For both machine perfusion and new sources of organs, XVIVO has a proven product line, and this puts XVIVO in a unique position in the market today. If we go to the next slide, number 21, this is more of a near-term outlook where I will maintain a razor-sharp focus on our key priorities, which are, we see, after this, we will have increased focus and actually spend more resources on both the US trial and launch preparation in Europe, Australia, and New Zealand. <bedroom /> For the same reason, we will also expand our global market leadership in lung by driving further EVLP utilization. Here the investment is mainly in marketing and field force capacity. I've said it many times before, but ramping up production capacity is the most important project we are running right now. To meet the increased demand we see for both kidneys and livers. So, we are focusing on that as well. And lastly, we have a clear focus on our service support for the growing U.S. transplant programs. So we will continue to drive, pilot, and develop successful product service revenue models to meet the logistical needs. We see transplant clinics have today to grow their programs and not burn out their staff. And so, with that, I will hand over for questions and remind everyone of the reason we are here, and it's that nobody should die waiting for a new organ. Thank you so much. <\br />

Operator
28:43 - 29:06

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Simon Lawson from Danske Bank. Please go ahead.

Unknown 2
29:08 - 29:34

Um, yes. Good afternoon, gentlemen. Um, two questions from my side, please. Uh, first, maybe on the long-term side of the business. Uh, so, as you said, two new express accounts that went live here during the quarter. I mean, would you say that these have contributed meaningfully to sales in the quarter, or should we expect them to ramp up further here during the back half of the year and support continued strong growth for the thorax segment?

Christoffer Rosenblad
29:35 - 29:57

Thank you, thank you. Great question. Uh, no. When there are active customers, they have already contributed during the quarter. So, that's the definition of a new customer: it's a meaningful contribution. Uh, um, so, what we are trying to do is build as many active customers as possible, to drive app usage.

Unknown 2
29:58 - 30:08

Yeah, yeah, yeah, of course, but I mean, I think I, I guess they are maybe not spending as much as a mature customer yet. Right? Or am I wrong?

Christoffer Rosenblad
30:09 - 30:21

I got the question. Yeah. I mean, there will be a ramp-up process. Uh, for sure. Uh, it's hard to say right now exactly how that will look. But yes, we anticipate that to be ramping up over time.

Unknown 2
30:22 - 30:53

Yeah. Okay. And I'll leave you with two questions. So my final one on the production scale-up project. So you're obviously pushing out the timeline here a little bit into the end of Q2 next year. So, I'm just trying to understand the risk of the current timeline that you have. So, what are the remaining boxes that you have to tick, so to speak, in order to finish this project? And is there any specific critical roadblock that you have to overcome to get to the factor ten in disposable volumes here?

Christoffer Rosenblad
30:54 - 32:02

Thank you. Thank you. Chairman, uh, just to be clear that when I left in June last year, I said it would take all in all two years. So, this is the timeline we always counted on and okay. But to answer the question, we are running according to the communicated time plan. The other thing, the part of the question where the critical components; there are a couple of key ones, which is one, investing in production equipment, which we have concluded. Uh, then there is of course, scale-up and validation of all production equipment and making sure we get notified by the FDA. Now, we don't foresee any delays in the project. And we are, as I stated, according to where we should be at this stage. Okay, but it's all in all for three products. Unfortunately, it is a two-year project. It is. That's the time it takes, unfortunately, to scale up this type of sterile production.

Operator
32:05 - 32:11

The next question comes from Jacob Lenka from SEB. During the Q2 earnings call, XVIVO Group highlighted several key accomplishments in the past quarter.

Unknown 3
32:13 - 32:39

Hello, and good afternoon or good morning, wherever you are in the world. Uh, my first question is on the line. Machine perfusion was obviously very strong here in Q2. Uh, my sense is that this is mainly driven by increased utilization at existing customers. But when you discuss with these customers, do you have any insights into what is driving this substantial increase in utilization?

Christoffer Rosenblad
32:41 - 32:57

Thank you for your question. Uh, I think there are mainly two reasons. On the one hand, the pressure. And this is mainly in the United States. One is mainly the pressure from.

Unknown 1
32:58 - 32:58

Uh.

Christoffer Rosenblad
32:59 - 33:55

American politicians from the beginning. But now, the transplant system has put pressure on scaling up volumes for transplants, which in turn increased the interest in performing EVLP, precisely the goal of EVLP, to make more organs available. Another factor driving significant interest, I believe, is what we achieve, particularly the realization that the technology can save and enable the transplantation of more organs, organs that previously would not have been considered usable. Uh, so those are the two main reasons we see for increased usage. And then I think running an LP, of course, takes some extra headcount, etc. So the hub models help to reduce the workload, and reduced workload will over time translate to higher usage.

Unknown 3
33:57 - 34:18

Okay, and just a short follow-up on that one. I mean, given that it seems like it's mostly external factors driving this, and you only recently did this reorganization in the US, is it fair to assume that growth could perhaps be even higher here going forward when you start to push it more and gain new accounts and so on.

Christoffer Rosenblad
34:19 - 34:53

And that is very hard to speculate on. We are very happy to see the progress in our sales team, especially in the US where we have made a real turnaround. Hope for the best. But it's hard to speculate where we see this going in the future, yet we observe good momentum. We will continue to work hard and see where we end up.

Unknown 3
34:55 - 35:05

Okay. Fair enough. And then, uh, moving on to kidney. Uh, when should we expect contributions from new customers now that you are able to take on those?

Christoffer Rosenblad
35:07 - 35:35

We believe that we will have the highest interest after Labor Day in September, because from now on, there will be a certain amount of holidays in the US on our customer side, which is starting up new programs. So, I think the contribution as of September is good for catering.

Unknown 3
35:37 - 35:55

Okay. And finally, I have a few questions on heart transplants. Maybe first, on the revenue side this quarter. Should we expect the Q2 revenues to be sort of the new normal, or should they come down a bit once? Recruitment in the US trial has finished?

Christoffer Rosenblad
35:56 - 36:35

From now until the trial is finished, we can probably maintain this level. And then when the trial is finished, it depends on the continuous protocol. That is something we are in dialogue with the FDA about. How that continuous protocol progresses and the number of transplants that will be involved. So, when the trial is finished by the end of March next year, it's hard to speculate at this moment what the level will look like. But up until then, I would assume the same level. Yes.

Unknown 3
36:37 - 36:47

Okay. But just looking at the revenue number here in Q2, if you continue at this pace, you will probably finish recruitment before March next year, right?

Christoffer Rosenblad
36:49 - 37:25

Yeah, we had a high level. Definitely, I always want to stick to the timeline we have, because you never know what happens in a trial. But I agree, there is a high interest. And right now, the inclusion in the trial is very dependent on how hard we work and what resources we allocate to include new trial centers into the study. But so far, the team has done a fantastic job. I'm truly proud of them.

Unknown 3
37:28 - 37:43

And if we move to Europe for heart transplants, how is the discussion with potential European customers and what expectations should we have for heart transplants in Europe once you have launched it?

Christoffer Rosenblad
37:44 - 38:44

We are preparing our launch plan right now. I will come back in Q3 and Q4 with more insights. But the good news, as you saw the trial starting now on direct procurement, DCD donors, for example, we have reported earlier on the Pegasus crossing over the Atlantic in a commercial flight trial, etc., the interest from European trial centers and the European heart transplant community is very high for this product. <sup><sup>So, that is definitely what we see right now. They want to push the boundaries and see what this technology really can accomplish. We are in the works right now to finalize how the launch plan will look and to give you more insights, but I need to come back in Q3, Q4 with a more precise answer on expectations, on activity level, etc..

Unknown 3
38:46 - 38:58

Okay. And finally, just a short run on this new DCD heart trial. Will there be any additional costs for that trial? And will you earn any revenue from the consumable in the trial?

Christoffer Rosenblad
38:59 - 39:10

Prior to seeing marks, we won't earn any revenue on it. There will be some additional costs, but.

Unknown 1
39:10 - 39:11

But.

Christoffer Rosenblad
39:11 - 39:20

They are in relation to the other trial costs in the US, etc. They are handleable and modest.

Unknown 3
39:22 - 39:24

Okay, that's all for me. Thank you very much.

Operator
39:32 - 39:36

The next question comes from Maria Vara from Bryan Garnier.

Maria Vara
39:40 - 40:01

Good afternoon. A very strong quarter. I just wanted to touch a bit on the service business. I think it's great, these new initiatives you are looking into. But I was just wondering, you know, how we'll see this actually impacting revenue and of course gross margin. Can you provide more details on this, please?

Christoffer Rosenblad
40:02 - 40:59

Thank you, Maria. Great question. We have a very high-quality service where we honestly had higher hopes on the revenue side; we think it's definitely worth that. It's a good one. Where we will work very hard is to incorporate it more into a product, service revenue where we think it plays better. Um, and we will generate more revenue. We will start that work. We have actually already started that work, so I hope to see the results of that soon. In terms of gross margin, how we report right now, I think the gross margin we see is reasonable to expect that we will maintain over time. I hope that answers your question.

Maria Vara
41:00 - 41:18

Yes. Just a bit on the heart trial recruitment process. If I remember correctly from the last quarter, you mentioned that ten out of twenty clinics had already initiated the trial. Do you have any updates on these numbers and any initial experiences or insights you want to share?

Christoffer Rosenblad
41:19 - 41:23

Yes, thank you. Um, yes, I can share. We are we.

Unknown 4
41:23 - 41:24

Are.

Christoffer Rosenblad
41:24 - 42:41

We are halfway through the time and halfway in terms of enrollment, and we have included more trial centers. I don't know the exact number right now, but we are continuing to add trial centers as quickly as we can because it takes some time to complete all the paperwork, get ethical approvals, and conduct the necessary training. The team is working really hard. Um, the initial feedback has been almost overwhelming from the users. The ease of using the product and how it effortlessly fits, not much larger than the beer cooler we previously used. And, uh, it doesn't need much more work. Actually, it's a bit of a back table before you go on the airplane. So far, the feedback on the product from both Europe, Australia, and the United States has been almost overwhelming. We have high hopes that this will translate into a successful launch on all continents, all the time.

Maria Vara
42:42 - 42:46

Great. That's great to hear. Well, that's everything from my side. Thank you very much.

Unknown 1
42:46 - 42:47

Thank you very much.

Operator
42:53 - 42:58

The next question comes from Johan, a nurse from Red Eye. Welcome to the XVIVO Group's Q2 2024 earnings call.

Unknown 5
43:02 - 43:31

Thank you. And congratulations on yet another strong quarter. And to start off with a few questions then. And, on the softer side, earlier in the previous quarter. I recall you mentioned a somewhat soft conversion in the pipeline for services, which seems to have continued into Q2 to some extent.

Christoffer Rosenblad
43:34 - 44:14

Yes, selling a service does indeed take a slightly longer time. As you may remember, we reorganized the sales team in late Q4 last year. We see early results on products more significantly than we do on services. But I'm confident that we will see good results over time for all our segments or areas. It is indeed true that selling a service generally takes a longer time than selling a product.

Unknown 1
44:14 - 44:15

Instant.

Unknown 5
44:17 - 44:35

And should we expect, uh. More support from the services side and in terms of pipeline conversion is expected due to the effect of the reorganization fairly soon, or is that something that will happen more into 2025, perhaps?

Christoffer Rosenblad
44:36 - 45:36

I think we will see a gradual improvement during Q3 and Q4. The long-term effect of the better product service revenue, I think we would need to look into more into 2025, or later. And I think it's also important to remember when we talk about service, where I believe the real 'holy grail,' so to speak, is definitely with the heart project or the heart product when we launch that. What I hear from customers is that we need to provide very good service along with our products. That being said, we are still expecting to see a gradual improvement over time.

Unknown 5
45:38 - 46:12

Already in Q2, you had another quarter which was very strong in overall sales. To some extent, this is somewhat ahead of scaling up the commercial structure, and I suspect that we should expect to see more OPEX growth reflecting the commercial US efforts, perhaps already in Q3. Could you provide a bit more clarity on what to expect on that side? Yes, certainly.

Christoffer Rosenblad
46:12 - 46:49

Thank you. First, we have the bigger picture; as I mentioned, a huge market potential exists, which we plan to invest in, where we believe the market will be, in units, ten times larger over time than what we observe today, and substantially more valuable in terms of value. That is, of course, what we are targeting towards the EBITDA 30% 2027 goal. So we always have a trade-off there. In terms of scaling up the field force, we have two.

Unknown 1
46:50 - 46:50

To.

Christoffer Rosenblad
46:50 - 47:09

Big milestones coming up. One is, of course, the kidney launch in the US where we will invest heavily. And that one is a hard launch in Europe. So, we will definitely face the need for investment into field force capabilities to ensure that we have a good launch for those two products in those two regions.

Unknown 5
47:12 - 47:35

Thank you for the background information. It's very useful in assisting with the editing process. And, uh, also regarding the discussions and communication with the FDA concerning the continuous protocol. You are in discussions, obviously. And what can we expect? Will we receive feedback from that before the study concludes, perhaps in March? Is it difficult to put a timetable on that?

Christoffer Rosenblad
47:37 - 47:48

Yes, it's difficult to put a timetable on it, precisely. From experience, we will probably know when we are near or at the end of the study.

Unknown 5
47:50 - 48:15

Yeah. Seems reasonable. And what about in Europe? It's sometimes, I mean, you had very good study results. The initial interest in heart technologies seems to be very strong, but Europe can sometimes be a tricky market to launch in. What's your take and approach in terms of key countries and types of centers?

Christoffer Rosenblad
48:16 - 49:26

You're right, Europe is probably the trickiest market to launch in, with numerous different countries, numerous different systems, and reimbursement being different in every country. So you're absolutely right. We will have a selected approach where we will launch almost center by center, because we have conducted the trial in eight countries. So we have a pretty good geographic footprint and experience with heart technology already established in Europe. But we will have a very targeted approach when we launch the heart in Europe due to the difference in systems and reimbursement country by country. We have a few target countries, like for example, France and Belgium, where we have very high interest, and we also know there is significant interest in Germany and the UK. So, we will ensure that we target effectively and maintain a very clear focus when we launch the hot product.

Unknown 5
49:27 - 49:30

Very good, very useful. Thanks. That's all from us.

Unknown 1
49:31 - 49:32

Thank you.

Operator
49:36 - 49:40

The next question comes from Ulrich Ratner from Carnegie.

Kristoffer Nordström
49:44 - 49:47

Thank you very much. Hi, Chris and Chris.

Unknown 6
49:48 - 50:41

Um, a lot of my questions have already been answered. Um, but I have a few additional ones. Abdominal. Um, and you're scaling up production. But as you mentioned, are you hitting your first milestone right now? Does that mean that you're ready to deliver on large, open contracts from the second half of this year? Or should we expect that the timeline will indeed tilt toward 2025, when you have cleared all obstacles related to production?

Christoffer Rosenblad
50:41 - 51:29

Thank you. That was very clarifying for our customers. The quick answer is that we should expect developments after Q2.

Year. And the reason is twofold. One is that we have increased the current production. We have increased quite dramatically, but not as much as we can, so let's go straight to the appeals. So, we're not there yet. There might be a couple of pitfalls. The second reason is that we want to collect more clinical data in the U.S. Ground, on kidneys. And that is best done in the clinical setting. Hence, at the clinics. So those are the two main reasons why I would expect that maybe in a year rather than now.

Unknown 6
51:30 - 52:15

Okay, great. Thanks for clarifying and follow-up question on the commercial launch of Kinesis Transport in the US and expanding your service offering. Is there more meaning for a service organization to expand within thoracic rather than in abdominal? Or are there similarities where you have high synergies, especially for the CAT machine? I think it's obvious if we look in hindsight on how you have delivered in Italy, that a perfusion service is a good way to get attachment, but is it as important for the CAT machine as it is for the rest of the products?

Christoffer Rosenblad
52:16 - 53:28

Um, that is a great question. I believe that due to the appeal system, that they are fairly used to pump kidney. But that being said, not all POs are providing pump services and not all kidneys go through POs. So I believe over time that will be important as well. Um, we are today. As I said before, we are focusing on scaling up the launch and gathering more and more clinical data on US soil, which looks very promising so far. Uh, presented at the ATC. Uh, from one center. Uh, so this will not be our focus in the launch phase. What we will focus on, on the Italian model or perfusion model is on the lung side, where we will pilot that in the US. Uh, but to answer your question more straightforwardly, we will not do it next year for the kidney. But we believe over time that that will be an important component also on the kidney assist transport launch.

Unknown 1
53:29 - 53:29

Okay.

Unknown 6
53:29 - 53:52

Great. Thank you very much. And the last question on my end would relate to liver and splitting the ID, um, and the liver being an important product and the US market being a huge commercial potential here. So what's left for you to submit an ID?

Unknown 1
53:53 - 53:54

Um.

Christoffer Rosenblad
53:55 - 54:36

There are a couple of tweaks on the product and the documentation to better fit the FDA that we need to do. Um, one example being that the delivery system we have in Europe can do both hypothermal and normal temperatures. Uh, what we plan to do, where we have the best clinical result, is on hypothermia. We need to, for example, limit the software so it can't go over a certain degrees. Uh, so there are a couple of reworks on the product and a couple of clarifications on the documentation to be done before we can hand in the ID.

Kristoffer Nordström
54:39 - 54:41

Okay, great.

Unknown 6
54:41 - 54:46

Um, those were all questions on my end. And I thank you very much and enjoy your summer.

Christoffer Rosenblad
54:47 - 54:49

Thank.What you very much. I hope you two enjoy your summer.

Operator
54:54 - 55:01

As a reminder, if you wish to ask a question, please dial the pound key followed by five on your telephone keypad.

Christoffer Rosenblad
55:03 - 55:04

Thank you.

Operator
55:05 - 55:11

The next question comes from Philip Forsberg from Perito Securities. Welcome to the XVIVO Group's second quarter 2024 earnings call.

Philip Forsberg
55:13 - 55:35

Hi, everyone. Um, just two questions here. One question is about the European centers that you mentioned, which you're going to focus on initially with the Heart Board books. Um, so in this country. So, what kinds of volumes do you have? Do you have any rough estimate of what kinds of volume they have? How many heart transplants do they perform?

Unknown 7
55:36 - 55:36

Um.

Christoffer Rosenblad
55:37 - 55:56

I don't have it right now, but that's a great question. The centers are high-volume centers in Europe. Uh, the exact number and the portion of the total European heart transplants. I need to come back with that at the next call. So we clarify that.

Philip Forsberg
55:58 - 56:13

All right. Thank you. Another question is whether there were any one-offs or extraordinary revenues in the quarter that we should consider moving forward. So, sales, academic orders that were pushed and other issues like that.

Unknown 1
56:14 - 56:14

Uh, no.

Christoffer Rosenblad
56:14 - 56:37

There were no such orders. The only thing that performed a little bit better than we thought, of course, was the heart trial in the US where they have the cost recovery model, and George, if that could be considered extra, but that was the only thing that was out of what we thought.

Philip Forsberg
56:38 - 56:40

Okay. That's all for me.

Operator
56:44 - 56:50

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Christoffer Rosenblad
56:51 - 57:09

I want to thank everyone for listening to this call. Remind everyone that on October 24th, we will release the Q3 report. We hope to have you all there listening to us then. And with that, I wish you all a great summer. Thank you so much.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…